

1 **Pre-conceptional maternal vitamin B12 supplementation improves offspring**
2 **neurodevelopment at 2 years of age: PRIYA trial**

3
4 **Type of manuscript: Brief Research Report**

5
6 Naomi D'souza^{1†}, Rishikesh V Behere^{1†}, Bindu Patni², Madhavi Deshpande², Dattatray Bhat¹,
7 Aboli Bhalerao¹, Swapnali Sonawane¹, Rohan Shah¹, Rasika Ladkat¹, Pallavi Yajnik¹,
8 Kalyanaraman Kumaran³, Caroline Fall³, Chittaranjan S Yajnik^{1*}.

9
10
11 1 - Diabetes Unit, KEM Hospital Research Center, Pune, India

12 2 - TDH Rehabilitation and Morris Child Development Centre at KEM Hospital, Pune

13 3 - MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, United
14 Kingdom

15
16
17
18 † The authors have contributed equally to this work and share first authorship

19 * **Corresponding author**

20 Dr Chittaranjan S Yajnik

21 Director, Diabetes Unit

22 KEM Hospital Research Center

23 489, Rasta Peth

24 Pune – 411011, India

25 Email: csyajnik@gmail.com

26 Ph: +919822847481

27
28 Number of Pages: 16

29 Word count: 3836

30 Number of Tables: 2

31 Number of figures: 2

32
33 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

34 **Abstract**

35 **Background:** Nutritional interventions during the first 1000 days of life improves lifelong
36 health. Better pre-conceptual maternal nutrition improves the nutrition of the early embryo.
37 Vitamins B12 and folate are important for fetal neural development. Vitamin B12 deficiency
38 is common in India.

39 **Methods:** In the Pune Rural Intervention in Young Adolescents (PRIYA) adolescents (N=557,
40 226 females) were provided with vitamin B12 (2µg/day) with or without multiple
41 micronutrients, or a placebo, from preconception until delivery. All groups received mandatory
42 iron and folic acid. We used the Bayley's Scale of Infant Development (BSID-III) at 24-42
43 months of age to investigate effects on offspring neurodevelopment. We examined cord blood
44 concentrations of brain-derived neurotropic factor (BDNF).

45 **Results:** Participants in the three groups had similar baseline B12 levels. These improved in
46 the B12 supplemented groups at pre-conceptual and pregnancy (28 weeks gestation)
47 measurements, reflected in higher cord holo-TC levels compared to the placebo.
48 Neurodevelopmental outcomes are available for 74 children. Offspring in the B12 alone group
49 (n=21) performed better than the placebo (n=27) on cognition (p=0.044) and language
50 (p=0.020) domains (adjusted for maternal baseline B12 levels). There were no differences
51 between the B12+MMN (n=26) and placebo group. Cord blood BDNF levels were highest in
52 the B12 alone group (not statistically significant).

53 **Conclusion:** Pre-conceptual vitamin B12 supplementation improved maternal B12 status
54 and offspring neurodevelopment at 2 years of age. The usefulness of cord BDNF as a marker
55 of brain development needs further investigation. Our results highlight the importance of
56 intervening in the pre-conceptual period.

57 **Key words:** Vitamin B12, pre-conception, supplementation, neurodevelopmental outcome,
58 offspring

59
60
61
62
63
64
65
66
67
68
69
70
71
72

73 1.0 Introduction

74 The developing fetus is dependent on its mother for its nutrition. Maternal undernutrition before
75 and during pregnancy affects fetal growth and development, the effects of which may predispose
76 an individual to undesirable outcomes in later life. This concept is called ‘fetal programming’.
77 This is the backbone for the Developmental Origins of Health and Disease (DOHaD) paradigm
78 (1,2). Pregnancy and the first two years of life (1000 days) are considered the most crucial window
79 for programming (3).

80 Maternal nutritional factors (both macro and micronutrients) influence neurodevelopmental
81 processes *in utero*, such as neurogenesis, myelination, synaptogenesis, and cortical brain growth
82 (3). Vitamins B12 and folate are of special interest due to their effects on cellular growth (DNA
83 synthesis, and epigenetic regulation by methylation) mediated by the one carbon metabolism
84 pathway (4). Offspring of mothers with low maternal vitamin B12 and folate during pregnancy
85 have a higher risk of neural tube defects and neurodevelopmental disorders (autism, ADHD),
86 poorer cognitive development and smaller brain volumes in childhood (5–8). In animal models
87 (rats), offspring of mothers exposed to a high folate and low vitamin B12 diet show lower levels
88 of the neurotrophic factor Brain Derived Neurotrophic Factor (BDNF) in the brain, and poorer
89 cognitive function (9,10).

90 In India, vitamin B12 deficiency is widely prevalent in pregnant women (50-70%) (11,12) and
91 is attributable to the socio-cultural practice of vegetarianism and poor economic status (13–
92 16). This deficiency is associated with a range of adverse pregnancy and offspring health
93 outcomes (17). In prospective birth cohorts (the Pune Maternal Nutrition study and the IAEA
94 B12 study) from western India, we have earlier shown that exposure to low maternal vitamin
95 B12 *in utero* is associated with poorer cognitive functioning at the age of 2 and 9 years in the
96 offspring (18,19). However, public health policy in India mandates only iron and folic acid
97 supplementation to women in the reproductive age group, and during pregnancy and lactation.
98 A randomized controlled trial in South India showed that supplementing 50 µg/day oral B12
99 from 14 weeks of pregnancy until 6 weeks postpartum improved B12 concentrations in breast
100 milk, the vitamin B12 status of infants at 6 weeks and infant cognitive function at 30 months
101 of age (20,21).

102 Important milestones in fetal neural development such as neural tube closure are completed by
103 26-28 days of gestation (22). The majority of pregnancies in India are unplanned, and by the
104 time pregnancy is detected (typically between 10-14 weeks gestation) this early developmental
105 window is lost. Pre-conceptional intervention will ensure that the mother has improved vitamin
106 stores during the early neurodevelopmental period. The success of pre-conceptional folic acid
107 supplementation in preventing neural tube defects is well known (23–25). Few studies have
108 examined the effects of pre-conceptional maternal micronutrient supplementation on offspring
109 neurodevelopment in India. This approach will expand the 1000 days concept to include the
110 pre-conceptional period.

111 The Pune Rural Intervention in Young Adolescents (PRIYA) is a pre-conceptional vitamin B12
112 and multi micronutrient supplementation trial in adolescent participants of the Pune Maternal
113 Nutrition Study. We report neurodevelopmental outcomes at 2 years of age in the offspring of
114 female participants of the trial. We hypothesised that pre-conceptional B12 supplementation in
115 the mothers would contribute to better neurodevelopmental outcomes in their offspring.

116

117

118

119 2.0 Material and Methods

120 2.1 *PRIYA* trial

121 The *PRIYA* trial methods have been previously published (26). Briefly, The Pune Maternal
122 Nutrition Study (PMNS) is a pre-conceptional observational birth cohort set up in 1993 (Figure
123 1). Non-pregnant women were recruited from six villages around Pune and those who became
124 pregnant were followed through pregnancy. Seven hundred and sixty-two children were born
125 and followed up serially. At age ~17 years, 690 participants from the PMNS cohort (11) were
126 screened for inclusion in the *PRIYA* trial. Of these, 133 were excluded due to severe vitamin
127 B12 deficiency or systemic illnesses. Five hundred and fifty-seven (266 females) participants
128 were randomized (Figure 1) to receive either a placebo, B12 (2µg/day) + multiple
129 micronutrients (MMN) or B12 alone (2µg/day). The composition of the MMN tablet was
130 guided by the WHO/UNICEF/UNU international multiple micronutrient preparation
131 (UNIMMAP), excluding folic acid because the mandated IFA tablets (100 mg elemental Iron
132 and 500 µg folic acid once a week) were given to all participants as per Government of India
133 recommendations. Female participants in the trial received supplementation daily until their
134 first delivery. They and the study team were blinded to the vitamin/micronutrient
135 supplementation.

136 Participants were followed up regularly for any health problems, and marriages were recorded.
137 Married women were monitored to detect pregnancy which was confirmed by a urine
138 pregnancy test. At 28 weeks gestation, mothers visited the Diabetes Unit, KEM Hospital
139 Research Center, Pune for evaluation. This included socio demographic information (assessed
140 using the Standard of Living Index questionnaire of the NFHS of India), anthropometry,
141 physical examination and blood measures of circulating vitamins B12, folate, B2 and B6. At
142 birth, delivery details and the baby's size were recorded. Maternal and cord blood samples were
143 collected.

144 These measurements were conducted in participants at baseline, 6-12 months after the start of
145 the intervention (at ~18 years of age), at 28 weeks gestation, and in cord blood. A Hemogram
146 was measured on a Beckman Coulter analyzer (Miami, Florida, USA) on the day of the
147 collection. Plasma vitamin B12 and folate were measured using a microbiological assay and
148 total homocysteine, vitamin B2 and B6 by HPLC as described in the *PRIYA* trial methods
149 publication (26). Plasma BDNF was measured in cord blood using ELISA (XpressBio)
150 (Frederick, USA)

151 2.2 *Neurodevelopmental assessments*

152 The offspring born in the trial were followed up every 6 months until 2 years of age, for
153 measurements of their growth. Once they reached 24 months of age, the parents were
154 approached regarding participation in the neuro-cognitive study, and their written informed
155 consent was obtained. An appointment was scheduled for the neurodevelopmental assessment
156 at the Child Development Center (TDH center), KEM Hospital, Pune. The child and mother
157 were transported to the center from their home on the morning of the assessment.

158 The neurodevelopmental assessment was performed using the Bayley's Scale of Infant
159 Development (BSID-III) (27). The BSID-III assesses the developmental status of infants from
160 1 to 42 months of age. The scales assess five domains across three main subscales: 1) cognitive
161 - which includes items such as attention to familiar and unfamiliar objects, looking for a fallen
162 object, and pretend play, 2) language - which assesses receptive and expressive language, via
163 recognition of objects and people, following directions, and naming objects and pictures, and
164 3) motor - which assesses gross and fine motor skills such as grasping, sitting, stacking blocks,

165 and climbing. The assessment was performed by trained clinical psychologists certified to
166 perform the BSID-III. Testing was carried out in a quiet room, with a parent or guardian
167 present, and instructions were provided in a language that was comfortable for the child. All
168 children were assessed within a time window of 24 to 42 months of age. Each test protocol was
169 independently reviewed and scored by two raters.

170 The BSID-III test yields raw scores based on the performance of the child on test items for
171 cognitive, expressive, and receptive communication, and fine and gross motor skills. The raw
172 scores were converted into age standardized scaled scores as recommended in the manual.
173 Summation of the scaled scores yields 3 composite scores for the cognitive, language and motor
174 skills domains. We used the composite scores in our analysis. Composite scores were
175 categorized into average, below or above average performance, based on standardized criteria
176 provided in the manual, where average is 100 with SD of 15 and a score of <85 is considered
177 to be below average (27).

178 As part of ongoing assessments in the PMNS cohort, maternal IQ was assessed in some of the
179 mothers at age 22~24 years using the Weschler's Adult Intelligence Scale-IV (WAIS-IV).

180 *2.3 Ethical considerations*

181 Details of community participation in the planning of this trial has been described earlier (26).
182 The trial was approved by the KEM Hospital Research Centre Ethics committee (no 1242) and
183 monitored by a Data Safety Monitoring Board (DSMB) and a Scientific Advisory Committee
184 (SAC). The trial was registered with the CTRI (2012/12/003212) and ISRCTN (32921044).
185 Neurodevelopmental assessment of the offspring was also approved by the Institutional ethics
186 committee of the KEM Hospital research center and registered in (clinical trials.gov ID:
187 NCT03088189).

188 *2.4 Statistical Analysis*

189 The purpose of our analysis was to see if pre-conceptual B12 and micronutrient
190 supplementation in the mothers led to improvement in offspring neurodevelopmental
191 performance (composite BSID-III scores) at 2 years of age. We also investigated the effect of
192 intervention on circulating vitamin levels in the mother and cord blood, and on cord blood
193 BDNF levels.

194 We first examined whether randomization had equally distributed potential confounders such
195 as parental education and standard of living index, and maternal age, IQ, and anthropometry,
196 across the three intervention groups.

197 All data were represented as either mean and standard deviation (for normally distributed
198 variables) or median inter-quartile range (IQR, for skewed variables). All right skewed
199 variables were log transformed. We used t-tests or ANOVA to test the significance of
200 differences in outcomes between the intervention groups, and ANCOVA to test the significance
201 of differences in outcomes between the intervention groups after adjusting for maternal B12
202 levels at screening. We used the Mann-Whitney U test to the significance of difference in cord
203 BDNF values between the intervention groups.

204

205 **3.0 Results**

206 Of the 266 women randomized in the trial, 182 were married, 166 became pregnant, and 149
207 delivered a live baby. Between May 2017 and February 2020, we approached the parents of 85
208 children who had attained the age of 2 years of age, for participation in the neurodevelopmental

209 study. Further assessments after February 2020 had to be halted due to the COVID-19
210 pandemic. None of the children had significant neurodevelopmental disorders (cerebral palsy,
211 seizure disorders, or neural tube defects). Seven children who were above the inclusion age of
212 42 months as per the BSID norms, were excluded from analysis after confirming that they had
213 achieved appropriate neurodevelopment for 42 months of age. Assessment could not be
214 completed in 4 children. Our analysis is based on the remaining 74 children. The median age
215 of the children at the time of performing the BSID was 29 months (Table1). There were 42
216 boys and 32 girls; of these, 27 were in the placebo group, 26 in the B12+MMN and 21 in the
217 B12 alone group. There were no differences in gestational age at delivery, birth weight, length
218 or head circumference amongst the offspring in the three intervention groups. Similarly, there
219 were no differences in parental education, standard of living index, maternal age, or IQ. (Table
220 1)

221 The children who were not invited for the study because they were below 24 months of age
222 differed from those studied; they had higher socio-economic status and parental education,
223 higher maternal and cord B12 and holotranscobalamin (holo-TC) and lower cord homocysteine
224 compared to the study group. (Supplementary Table 1).

225 *3.1 Effect of supplementation on maternal and newborn micronutrient status, and birth* 226 *measures*

227 At baseline, maternal B12 and holo-TC levels were similar across the three intervention groups
228 (Table 1). Fifty one percent of the females had vitamin B12 deficiency at screening (B12<150
229 pM), and this reduced to 22% at 6-12 months after starting intervention. There was a rise in
230 vitamin B12 and holo-TC levels in the B12 supplemented groups compared to the placebo
231 group, both pre-conceptionally (18 years of age) and at 28 weeks of gestation. Cord blood
232 levels of holo-TC were significantly higher in the B12 supplemented groups compared to the
233 placebo group, though B12 levels were similar.

234 Plasma homocysteine concentrations which were high but similar at baseline in the three
235 groups of mothers, fell substantially in the vitamin B12 supplemented groups pre-
236 conceptionally. During pregnancy, as expected, plasma homocysteine concentrations fell in all
237 groups and were similar in the three groups during pregnancy as well as in cord blood.

238 Circulating folate concentrations were similar at baseline in the three groups and increased
239 during pregnancy (due to supplementation). Folate levels were significantly lower at 28 weeks
240 gestation in the B12+MMN group as compared to the placebo. Folate levels were similar in the
241 cord blood across the groups. Circulating vitamin B2 and B6 concentrations increased from
242 baseline in the B12 +MMN group before and during pregnancy and in cord blood.

243 Hemoglobin concentrations were similar in the mother and the baby across all the groups.

244 *3.2 Comparison of BSID scores and cord BDNF between supplementation groups*

245 Age standardized composite scores in the domains of cognition, motor and language
246 development were obtained on 74 children. There was no difference in performance between
247 males and females (supplementary Table 3). No significant developmental delays were
248 observed in any of the children (score < 69). Few children showed a below average
249 performance on the cognitive (4.0%, n=3), motor (4.0%, n=3), and language domain (8.1%,
250 n=6) (score < 85) (supplementary table 2).

251 The offspring of mothers in the B12 alone group performed the best in the cognitive and
252 language domains, and significantly better than the placebo group (Table 2). This difference
253 persisted after adjusting for the baseline plasma vitamin B12 concentrations, the latter were not

254 related to neurodevelopmental outcomes. There was a 5 -7% increase in cognition and language
255 composite scores in the B12 alone group over the placebo group.

256 There were no significant differences between the B12+MMN group and the placebo group on
257 any of the neurodevelopmental subscales.

258 The two intervention groups had higher cord BDNF values than the placebo group, the B12
259 alone group had the highest values, however the difference was non-significant (Table 1). Cord
260 blood BDNF values did not show significant associations with any of the BSID-III composite
261 scores.

262

263 **4.0 Discussion**

264 In this rural Indian population with a substantial prevalence of B12 deficiency, we found that
265 supplementation of adolescents with 2 µg /day of B12 significantly improved their own B12
266 status (total B12 and holo-TC) and cord blood holo-TC. Offspring whose mothers received
267 vitamin B12 alone performed better than offspring of mothers in the placebo group in
268 neurodevelopmental assessments (cognitive and language domain of the BSID-III test at 24-
269 42 months of age). Offspring whose mothers received B12+MMN performed similarly to the
270 placebo group.

271 The role of pre-conceptional folic acid supplementation in preventing NTDs is well established,
272 especially in western (mainly non-vegetarian) populations (23,24). In vegetarian populations
273 like India, vitamin B12 is likely to play a similar role, probably because both folate and B12
274 act as cofactors for the enzyme methionine synthase, in methylation reactions. Studies in India
275 have highlighted an association of both maternal vitamin B12 and folate with different
276 outcomes in the offspring including neurodevelopmental performance. Studies in Pune showed
277 an association of low maternal vitamin B12 status (low holo-TC concentrations and TCN2
278 polymorphisms) with risk of NTD, and a positive association between maternal vitamin B12
279 status during pregnancy and offspring neurocognitive performance at 2 and 9 years of age
280 (5,18,19). A study in North Indian children aged 12–18 months found that both vitamin B12
281 and folate status had significant associations with cognitive performance (28) while a study in
282 Mysore found that higher maternal folate concentrations, but not vitamin B12, during
283 pregnancy were associated with better cognitive ability in children at 9-10 years of age (29).
284 Adequate status of both vitamins is likely to be important for brain development and function.
285 Recent systematic reviews, including both observational and interventional studies, support a
286 moderate level of evidence for a role of maternal B12 status in determining offspring cognitive
287 function, and highlight a need for more studies from developing countries (17,30). Studies in
288 Mexico and Singapore have also reported an association between maternal dietary intake of
289 vitamin B12 and offspring cognitive abilities (31,32). Observations in the ALSPAC cohort in
290 the UK suggests a weak association of maternal a genetic determinant of circulating vitamin
291 B12 concentrations (*FUT2*) and offspring IQ at 8 years of age (33). On the other hand, a cohort
292 study in Canada, showed no significant associations between maternal vitamin B12
293 concentrations and BSID-III outcomes in their offspring at 18 months (32). This may be due
294 to a lack of significant variation in maternal vitamin B12 status, given the low prevalence of
295 vitamin B12 deficiency in their population (34).

296 Our findings from this pre-conceptional maternal micronutrient supplementation trial fills an
297 important gap in the literature. Our observations are supported by a maternal B12
298 supplementation study from south India, which supplemented mothers with 50 µg vitamin B12
299 from the 1st trimester of pregnancy until 6 weeks postpartum. Supplementation improved

300 maternal B12 levels in the third trimester (20) and offspring showed a better
301 neurodevelopmental outcome (language domain) at 30 months of age (21). Vitamin B12 (1.8
302 µg) and/or folic acid (150 µg) supplementation in 6–30-month-old children for a period of 6
303 months showed improvement in their neurocognitive performance. The B12 alone group
304 showed improvement in gross motor functioning and the B12 + folic acid group in gross motor
305 as well as problem-solving functioning compared to the placebo; folic acid alone had no effect
306 (35).

307 The wide prevalence of B12 deficiency is unique to the Indian context due to the socio-cultural
308 practice of vegetarianism. Severe absorption defects (i.e. pernicious anaemia) are rare and
309 vitamin B12 deficiency is largely a low dietary intake problem (15–18). This offers a unique
310 opportunity to control a modifiable risk factor at the public health scale to improve
311 neurodevelopment and human capital in the next generation. Our choice of a near-
312 recommended dietary allowance (RDA) dose of B12 (2 µg/day) was based on our earlier
313 studies showing adequate absorption of oral B-12 (36) in this population and the demonstration
314 in a pilot study of improvement in B-12 and homocysteine status after oral supplementation for
315 1 year (37). In another study of severely B12 deficient girls, (plasma B12 <100 pmol/l) we
316 demonstrated an improvement in haematological parameters and peripheral and autonomic
317 nerve functions after supplementing 2 µg/day of vitamin B12 for 11 months (38). Thus, we
318 believe that our current study fills an important gap to help public health policy to supplement
319 a physiological dose of vitamin B12 to adolescents and reproductive age women to improve
320 not only their own health but also that of the next generation. Being aware of the difficulties of
321 achieving long term compliance with tablet supplementation in relatively asymptomatic
322 individuals, we have recently reported the efficacy of commonly eaten vitamin fortified food
323 items (nutrient bar and yogurt) to achieve better vitamin B12 status (39). All these approaches
324 are usable in the national programmes to improve micronutrient nutrition of children,
325 adolescents and pregnant mothers.

326 The improved cognitive outcomes were seen specifically in the B12 alone supplemented group
327 and not in the B12+MMN group. The B12 alone group achieved higher cord B12, holo-TC and
328 BDNF levels compared to the B12+MMN group, despite a similar daily dose of B12. Though
329 we are unsure about the reason for this difference, the possibilities include differences in
330 compliance and absorption. Evidence for the effects of maternal multiple micronutrient
331 supplementation on offspring outcomes is inconsistent. A systematic review from 9 trials (6 of
332 which used UNIMAP micronutrient composition) did not find favourable effects on child
333 mortality, birth size, or offspring cognition (40).

334 Vitamins B12 and folate participate in the one-carbon metabolism pathway to 1) stimulate
335 synthesis of precursor nucleotides for DNA synthesis, and 2) generate the universal methyl
336 donor S-Adenosyl methionine (SAM) which is involved in methylation of DNA (an important
337 epigenetic mechanism), proteins and lipids and generating neurotransmitters(41,42). These
338 mechanisms are reputedly involved in fetal growth and differentiation and a deficiency or
339 imbalance of these may result in permanent change in the structure and function of developing
340 tissues which may manifest as disorders in later life ('fetal programming') (1). We have
341 demonstrated alterations in adiposity and insulin resistance in children whose mothers had an
342 imbalance of these vitamins (low B12 – high folate) during pregnancy (11). Animal studies
343 have shown differences in the expression of neurotrophic factors such as BDNF in the brains
344 of fetuses whose mothers were exposed to low vitamin B12 status (9). In our study, though we
345 did not find significant differences in cord blood BDNF concentrations between intervention
346 groups, the values tended to be higher in the B12 alone group. Further studies are required to
347 understand the utility of cord BDNF levels as a neurodevelopmental marker in human beings.

348 Neurodevelopment is a dynamic process that involves neurogenesis, neuronal migration,
349 cortical growth and gyrification, starting in early pregnancy and lasting until infancy (first 1000
350 days). The pre- and periconceptual period is an important window within this broader
351 window because of ‘epigenetic reprogramming’ of the conceptus which happens within 48-72
352 hours of conception(43). The majority of pregnancies are unplanned, and women approach the
353 healthcare system after this window. Our intervention was specifically started in adolescence
354 to ensure adequate micronutrient stores in the mother from before conception, in time to
355 support gametogenesis, conception, embryogenesis, organogenesis, and placentation. (42,44).
356 The success of pre-conceptual folic acid supplementation in preventing NTDs is well known
357 (23–25). Thus, we propose that the 1000-day window should be expanded to include the
358 preconception period. This would shift the action from the clinic to the community and will fit
359 well into a multitude of adolescent and reproductive age programs across the world.

360 Additional strengths of our study include a trial within a cohort in which original observations
361 were made, the RCT design which ensured that potential confounders were similarly
362 distributed between allocation groups. For example, home environmental factors that can
363 influence child neurodevelopment - parental education, maternal IQ and socio-economic
364 status- were similar across intervention groups. High rates of participation in the trial, high
365 rates of follow up, and of sample collection at delivery are also noteworthy. Exclusion of
366 women with severe B12 deficiency (<100pM) from a placebo-controlled trial on ethical
367 grounds reduced the power of the study because they and their offspring could have benefited
368 the most with B12 intervention. The COVID pandemic also interfered with our ability to test
369 more children for neurodevelopment and meant that we missed the children of women who
370 became pregnant later and at older ages. Despite these limitations we were able to see the
371 beneficial effects of the intervention. We expect that the performance on the Bayley’s scale,
372 will reflect in neurodevelopment indices at a later age. This will be tested in subsequent follow
373 ups.

374 **5.0 Summary and Conclusion**

375 We found that pre-conceptual maternal supplementation with a near RDA dose (2 µg/day) of
376 vitamin B12 exposed their offspring to higher vitamin B12 status peri-conceptionally and
377 during pregnancy. This was associated with better neurodevelopmental performance in the
378 children, in cognitive and language domains, between 24-42 months of age. Our study
379 highlights an important role for maternal vitamin B12 on offspring neurodevelopment. We urge
380 that the first 1000 days window be extended to include the pre-conceptual period. Our
381 findings have strong implications for public health policy to improve vitamin B12 status of
382 young adolescents and reproductive age women in populations with a sizable vitamin B12
383 deficiency. We foresee benefits of such a policy to many national nutrition programmes in
384 India.

385

386 **Figure 1 Consort depicting the recruitment of study participants**

387 **Figure 2 Bar graph showing comparison between placebo and treatment groups on BSID-**
388 **III domains**

389

390

391

392 **Authors contributor statement**

393

394 CSY and RVB designed the neurocognitive follow-up study. ND and RVB analysed the data
395 and wrote the first draft. BP and MD performed and reported the neurocognitive assessments.
396 DB performed the biochemical measurements. AB contributed to the statistical analysis. SS
397 and RS conducted the follow-up of the participants. KK, RL, and PY contributed to conducting
398 the PRIYA trial. CSY and CF designed the original PRIYA trial. CSY and CF edited the final
399 manuscript. All authors contributed to the article and approved the submitted version.

400 **Conflicts of Interest**

401 The authors declare that they have no conflicts of interest.

402 **Acknowledgments**

403

404 We are grateful to the participants of the PMNS for their cooperation in this trial. We
405 acknowledge the contribution of the field workers - Mr Ankush Bhalerao, Mr Suresh Chougule,
406 Mr Vishnu Solat and Ms Rajani Bendge, Ms Malti Raut, Ms Mangal Gaikwad, Ms Sujata
407 Jagtap, Ms Sarla Bagate, Ms Jayshri Kalokhe in conducting the trial. We thank Ms Anagha
408 Deshmukh, Ms Sarah Khan, Ms Deepa Raut, Ms Sayali Wadke, Ms Rajashree Kamat for their
409 assistance in data collection.

410

411 **Funding**

412

413 The PRIYA trial is funded by the Indian Council of Medical Research (58/1/8/
414 MRC-ICMR/2009/NCD-II) and Medical Research Council, UK (MR/J000094/1) as
415 part of an Indo-UK collaborative call.

416 The biological sample collection and analysis was funded by the DBT-CEIB grant
417 BT/PR12629/MED/97/364/2016

418 The neurocognitive follow up and cord BDNF measurements was supported by the
419 DBT/Wellcome India Alliance Fellowship [IA/CPHI/161502665] awarded to RB.

420 CSY was visiting professor at Danish Diabetes Academy & Southern University of Denmark
421 (2016-2018) which was funded by NOVO-NORDISK FONDEN.

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440 **References**

- 441 1. Lucas A. Programming by early nutrition in man. *Ciba Found Symp.* 1991;156:38–50;
442 discussion 50-55.
- 443 2. Barker DJP. The origins of the developmental origins theory. *J Intern Med.* 2007
444 May;261(5):412–7.
- 445 3. Cusick SE, Georgieff MK. The Role of Nutrition in Brain Development: The Golden
446 Opportunity of the “First 1000 Days.” *J Pediatr.* 2016 Aug;175:16–21.
- 447 4. Kalhan SC. One carbon metabolism in pregnancy: Impact on maternal, fetal and neonatal
448 health. *Mol Cell Endocrinol.* 2016 Nov;435:48–60.
- 449 5. Godbole K, Gayathri P, Ghule S, Sasirekha BV, Kanitkar-Damle A, Memane N, et al.
450 Maternal one-carbon metabolism, MTHFR and TCN2 genotypes and neural tube defects
451 in India. *Birt Defects Res A Clin Mol Teratol.* 2011 Sep;91(9):848–56.
- 452 6. Suren P, Roth C, Bresnahan M, Haugen M, Hornig M, Hirtz D, et al. Association
453 between maternal use of folic acid supplements and risk of autism spectrum disorders in
454 children. *JAMA.* 2013;309–6.
- 455 7. Ars CL, Nijs IM, Marroun HE, Muetzel R, Schmidt M, Steenweg-de Graaff J, et al.
456 Prenatal folate, homocysteine and vitamin B12 levels and child brain volumes, cognitive
457 development and psychological functioning: the Generation R Study. *Br J Nutr.* 2016 Jan
458 22;1–9.
- 459 8. Schlotz W, Phillips DI. Fetal origins of mental health: evidence and mechanisms. *Brain*
460 *Behav Immun.* 2009;23(7):905–16.
- 461 9. Sable P, Dangat K, Kale A, Joshi S. Altered brain neurotrophins at birth: consequence of
462 imbalance in maternal folic acid and vitamin B12 metabolism. *Neuroscience.* 2011
463 Sep;190:127–34.
- 464 10. Sable PS, Kale AA, Joshi SR. Prenatal omega 3 fatty acid supplementation to a
465 micronutrient imbalanced diet protects brain neurotrophins in both the cortex and
466 hippocampus in the adult rat offspring. *Metabolism.* 2013 Nov;62(11):1607–22.
- 467 11. Yajnik CS, Deshpande SS, Jackson AA, Refsum H, Rao S, Fisher DJ, et al. Vitamin B12
468 and folate concentrations during pregnancy and insulin resistance in the offspring: the
469 Pune Maternal Nutrition Study. *Diabetologia.* 2007 Nov 29;51(1):29–38.
- 470 12. Finkelstein JL, Kurpad AV, Thomas T, Srinivasan K, Duggan C. Vitamin B12 status in
471 pregnant women and their infants in South India. *Eur J Clin Nutr.* 2017;71(9):1046–53.
- 472 13. Chanarin I, O’Hea A-M, Malkowska V, Rinsler MG, Price AB. MEGALOBlastic
473 ANAEMIA IN A VEGETARIAN HINDU COMMUNITY. *The Lancet.* 1985
474 Nov;326(8465):1168–72.
- 475 14. Price SR. Observations on dietary practices in India. *Hum Nutr Appl Nutr.* 1984
476 Oct;38(5):383–9.

- 477 15. Jathar VS, Inamdar-Deshmukh AB, Rege DV, Satoskar RS. Vitamin B₁₂ and
478 Vegetarianism in India. *Acta Haematol.* 1975;53(2):90–7.
- 479 16. Yajnik CS, Deshpande SS, Lubree HG, Naik SS, Bhat DS, Uradey BS, et al. Vitamin
480 B12 deficiency and hyperhomocysteinemia in rural and urban Indians. *J Assoc*
481 *Physicians India.* 2006 Oct;54:775–82.
- 482 17. Behere RV, Deshmukh AS, Otiv S, Gupte MD, Yajnik CS. Maternal Vitamin B12 Status
483 During Pregnancy and Its Association With Outcomes of Pregnancy and Health of the
484 Offspring: A Systematic Review and Implications for Policy in India. *Front Endocrinol.*
485 2021 Apr 12;12:619176.
- 486 18. Bhate V, Deshpande S, Bhat D, Joshi N, Ladkat R, Watve S, et al. Vitamin B₁₂ Status of
487 Pregnant Indian Women and Cognitive Function in their 9-year-old Children. *Food Nutr*
488 *Bull.* 2008 Dec;29(4):249–54.
- 489 19. Bhate VK, Joshi SM, Ladkat RS, Deshmukh US, Lubree HG, Katre PA, et al. Vitamin
490 B12 and folate during pregnancy and offspring motor, mental and social development at
491 2 years of age. *J Dev Orig Health Dis.* 2012 Apr;3(2):123–30.
- 492 20. Duggan C, Srinivasan K, Thomas T, Samuel T, Rajendran R, Muthayya S, et al. Vitamin
493 B-12 Supplementation during Pregnancy and Early Lactation Increases Maternal, Breast
494 Milk, and Infant Measures of Vitamin B-12 Status. *J Nutr.* 2014 May 1;144(5):758–64.
- 495 21. Thomas S, Thomas T, Bosch RJ, Ramthal A, Bellinger DC, Kurpad AV, et al. Effect of
496 Maternal Vitamin B12 Supplementation on Cognitive Outcomes in South Indian
497 Children: A Randomized Controlled Clinical Trial. *Matern Child Health J.* 2019
498 Feb;23(2):155–63.
- 499 22. Greene NDE, Copp AJ. Neural Tube Defects. *Annu Rev Neurosci.* 2014 Jul 8;37(1):221–
500 42.
- 501 23. Wald N, Sneddon J, Densem J, Frost C, Stone R. Prevention of neural tube defects:
502 results of the Medical Research Council Vitamin Study. *Lancet.* 1991;338(8760):131–7.
- 503 24. Czeizel AE, Dobó M, Vargha P. Hungarian cohort-controlled trial of periconceptional
504 multivitamin supplementation shows a reduction in certain congenital abnormalities. *Birt*
505 *Defects Res A Clin Mol Teratol.* 2004 Nov;70(11):853–61.
- 506 25. Central Technical Co-ordinating Unit, ICMRCentral Technical Co-ordinating Unit,
507 ICMR. Multicentric study of efficacy of periconceptional folic acid containing vitamin
508 supplementation in prevention of open neural tube defects from India. *Indian J Med Res.*
509 2000 Dec;112:206–11.
- 510 26. Kumaran K, Yajnik P, Lubree H, Joglekar C, Bhat D, Katre P, et al. The Pune Rural
511 Intervention in Young Adolescents (PRIYA) study: design and methods of a randomised
512 controlled trial. *BMC Nutr [Internet].* 2017 Dec [cited 2019 Jan 22];3(1). Available from:
513 <http://bmcnutr.biomedcentral.com/articles/10.1186/s40795-017-0143-5>
- 514 27. Bayley N. Bayley Scales of Infant and Toddler Development: Bayley-III. Harcourt
515 Assessment, Psych.Corporation; 2006.

- 516 28. Strand TA, Taneja S, Ueland PM, Refsum H, Bahl R, Schneede J, et al. Cobalamin and
517 folate status predicts mental development scores in North Indian children 12-18 mo of
518 age. *Am J Clin Nutr*. 2013 Feb;97(2):310–7.
- 519 29. Veena SR, Krishnaveni GV, Srinivasan K, Wills AK, Muthayya S, Kurpad AV, et al.
520 Higher maternal plasma folate but not vitamin B-12 concentrations during pregnancy are
521 associated with better cognitive function scores in 9- to 10- year-old children in South
522 India. *J Nutr*. 2010 May;140(5):1014–22.
- 523 30. Veena SR, Gale CR, Krishnaveni GV, Kehoe SH, Srinivasan K, Fall CH. Association
524 between maternal nutritional status in pregnancy and offspring cognitive function during
525 childhood and adolescence; a systematic review. *BMC Pregnancy Childbirth*. 2016
526 Dec;16(1):220.
- 527 31. del Río Garcia C, Torres-Sánchez L, Chen J, Schnaas L, Hernández C, Osorio E, et al.
528 Maternal *MTHFR* 677C>T genotype and dietary intake of folate and vitamin B₁₂: their
529 impact on child neurodevelopment. *Nutr Neurosci*. 2009 Feb;12(1):13–20.
- 530 32. Lai JS, Mohamad Ayob MN, Cai S, Quah PL, Gluckman PD, Shek LP, et al. Maternal
531 plasma vitamin B12 concentrations during pregnancy and infant cognitive outcomes at 2
532 years of age. *Br J Nutr*. 2019 Jun;121(11):1303–12.
- 533 33. Bonilla C, Lawlor DA, Ben-Shlomo Y, Ness AR, Gunnell D, Ring SM, et al. Maternal
534 and offspring fasting glucose and type 2 diabetes-associated genetic variants and
535 cognitive function at age 8: a Mendelian randomization study in the Avon Longitudinal
536 Study of Parents and Children. *BMC Med Genet*. 2012 Sep 27;13:90.
- 537 34. Wu BTF, Dyer RA, King DJ, Richardson KJ, Innis SM. Early Second Trimester Maternal
538 Plasma Choline and Betaine Are Related to Measures of Early Cognitive Development in
539 Term Infants. Szecsi PB, editor. *PLoS ONE*. 2012 Aug 20;7(8):e43448.
- 540 35. Kvestad I, Taneja S, Kumar T, Hysing M, Refsum H, Yajnik CS, et al. Vitamin B12 and
541 Folic Acid Improve Gross Motor and Problem-Solving Skills in Young North Indian
542 Children: A Randomized Placebo-Controlled Trial. Cameron DW, editor. *PLOS ONE*.
543 2015 Jun 22;10(6):e0129915.
- 544 36. Bhat DS, Thuse NV, Lubree HG, Joglekar CV, Naik SS, Ramdas LV, et al. Increases in
545 plasma holotranscobalamin can be used to assess vitamin B-12 absorption in individuals
546 with low plasma vitamin B-12. *J Nutr*. 2009 Nov;139(11):2119–23.
- 547 37. Deshmukh US, Joglekar CV, Lubree HG, Ramdas LV, Bhat DS, Naik SS, et al. Effect of
548 physiological doses of oral vitamin B12 on plasma homocysteine: a randomized, placebo-
549 controlled, double-blind trial in India. *Eur J Clin Nutr*. 2010 May;64(5):495–502.
- 550 38. Yajnik CS, Behere RV, Bhat DS, Memane N, Raut D, Ladkat R, et al. A physiological
551 dose of oral vitamin B-12 improves hematological, biochemical-metabolic indices and
552 peripheral nerve function in B-12 deficient Indian adolescent women. Loo JJ, editor.
553 *PLOS ONE*. 2019 Oct 10;14(10):e0223000.
- 554 39. Yajnik C, Kasture S, Kantikar V, Lubree H, Bhat D, Raut D, et al. Efficacy of B₁₂
555 Fortified Nutrient Bar and Yogurt in Improving Plasma B12 Concentrations—Results

- 556 From 2 Double-Blind Randomized Placebo Controlled Trials. *Food Nutr Bull.* 2021 Jun
557 30;037957212110254.
- 558 40. Devakumar D, Fall CHD, Sachdev HS, Margetts BM, Osmond C, Wells JCK, et al.
559 Maternal antenatal multiple micronutrient supplementation for long-term health benefits
560 in children: a systematic review and meta-analysis. *BMC Med.* 2016 Jun 16;14:90.
- 561 41. Green R, Allen LH, Bjørke-Monsen A-L, Brito A, Guéant J-L, Miller JW, et al. Vitamin
562 B12 deficiency. *Nat Rev Dis Primer.* 2017 Dec 21;3(1):17040.
- 563 42. Fleming TP, Watkins AJ, Velazquez MA, Mathers JC, Prentice AM, Stephenson J, et al.
564 Origins of lifetime health around the time of conception: causes and consequences.
565 *Lancet Lond Engl.* 2018 May 5;391(10132):1842–52.
- 566 43. Amoako AA, Nafee TM, Ola B. Epigenetic Influences During the Periconception Period
567 and Assisted Reproduction. In: Fazeli A, Holt WV, editors. *Periconception in Physiology
568 and Medicine* [Internet]. Cham: Springer International Publishing; 2017 [cited 2021 Jul
569 14]. p. 15–39. (*Advances in Experimental Medicine and Biology*; vol. 1014). Available
570 from: http://link.springer.com/10.1007/978-3-319-62414-3_2
- 571 44. Steegers-Theunissen RPM, Twigt J, Pestinger V, Sinclair KD. The periconceptional
572 period, reproduction and long-term health of offspring: the importance of one-carbon
573 metabolism. *Hum Reprod Update.* 2013 Nov 1;19(6):640–55.
- 574
- 575
- 576
- 577
- 578
- 579
- 580
- 581
- 582
- 583
- 584
- 585
- 586
- 587
- 588
- 589
- 590

591 **Table 1.** Maternal characteristics at baseline and pregnancy, and child characteristics

| Variables | n | Placebo Group | n | B12+MMN Group | n | B12 Group | p values | |
|--|----|----------------------|----|----------------------|----|----------------------|--------------------------------------|----------------------------------|
| Parental sociodemographic characteristics | | | | | | | | |
| Maternal age at 28 weeks gestation (years) | 25 | 19.8 (1.0) | 25 | 19.4 (1.1) | 21 | 19.7 (1.1) | 0.555 | |
| Maternal education (years) | 26 | 12.5 (11.0,13.0) | 26 | 12.0 (10.0, 13.0) | 21 | 12.0 (11.0, 13.5) | 0.639 | |
| Maternal height (cms) | 25 | 158.2 (5.2) | 25 | 158.7 (5.0) | 21 | 157.8 (4.8) | 0.852 | |
| Maternal weight at 28 weeks gestation (kgs) | 25 | 55.4 (48.6, 59.3) | 25 | 51.2 (49.4, 54.4) | 21 | 52.9 (47.0, 60.7) | 0.656 | |
| Maternal IQ | 21 | 76.6 (9.5) | 15 | 74.4 (8.8) | 17 | 75.8 (7.2) | 0.751 | |
| Standard of Living Index | 26 | 36.0 (30.5, 40.5) | 26 | 38.0 (31.0, 40.0) | 21 | 37.0 (32.0, 40.0) | 0.923 | |
| Paternal Education (years) | 25 | 14.0 (10.5, 15.0) | 24 | 12.0 (10.0, 15.0) | 19 | 12.0 (10.0, 15.0) | 0.656 | |
| Maternal Micronutrients | | | | | | | p values (B12+MMN vs Placebo) | p values (B12 vs Placebo) |
| At screening | | | | | | | | |
| Vitamin B12 (pM) | 27 | 151.0 (122.0, 193.0) | 26 | 159.5 (134.0, 219.0) | 21 | 138.0 (125.0, 190.0) | 0.350 | 0.860 |
| Folate (nM) | 27 | 20.9 (15.3, 24.6) | 26 | 15.7 (11.3, 26.6) | 21 | 20.8 (15.3, 29.1) | 0.357 | 0.698 |
| Homocysteine (µmol/L) At 18 years | 27 | 20.1 (15.1, 38.0) | 26 | 18.6 (15.3, 30.3) | 21 | 27.5 (17.0, 39.6) | 0.646 | 0.434 |
| Vitamin B12 (pM) | 25 | 162.0 (125.9, 192.5) | 26 | 285.0 (205.8, 368.7) | 18 | 274.7 (224.7, 388.2) | <0.001*** | <0.001*** |
| Folate (nM) | 26 | 23.0 (17.2, 29.8) | 26 | 21.2 (15.3, 28.8) | 18 | 20.4 (14.9, 28.3) | 0.734 | 0.925 |
| Homocysteine (µmol/L) | 27 | 16.7 (11.7, 28.3) | 26 | 9.60 (8.30, 13.4) | 18 | 10.6 (9.22, 16.0) | <0.001*** | 0.013* |
| At 28 weeks gestation | | | | | | | | |
| Hemoglobin (gm/dl) | 25 | 10.4 (9.5, 11.0) | 25 | 10.2 (9.4, 11.0) | 21 | 10.4 (9.1, 10.7) | 0.491 | 0.638 |
| Vitamin B12 (pM) | 25 | 134.0 (95.5, 163.0) | 25 | 164.0 (149.0, 218.5) | 21 | 204.0 (173.5, 261.0) | 0.007** | <0.001*** |
| Holo-TC (pM) | 25 | 14.8 (8.85, 25.1) | 25 | 21.9 (15.3, 36.5) | 21 | 21.3 (16.9, 36.8) | 0.027* | 0.012* |
| Folate (nM) | 25 | 47.9 (18.0, 71.5) | 25 | 20.6 (10.2, 49.7) | 21 | 28.5 (16.6, 51.4) | 0.043* | 0.302 |
| Vitamin B2 (pM) | 25 | 244.0 (210.5, 273.0) | 25 | 276.0 (229.5, 304.5) | 20 | 244.0 (221.7, 269.5) | 0.028* | 0.852 |
| Vitamin B6-pyridoxal-5-phosphate (pM) | 24 | 3.5 (2.3, 4.6) | 25 | 4.6 (3.3, 7.4) | 21 | 3.1 (2.6, 4.8) | 0.117 | 0.357 |
| Vitamin B6-pyridoxal (pM) | 15 | 1.0 (0.8, 1.6) | 12 | 1.1 (0.9, 1.3) | 12 | 1.3 (1.0, 1.7) | 0.786 | 0.922 |
| Homocysteine (µmol/L) | 25 | 7.0 (5.0, 9.2) | 25 | 6.3 (4.3, 8.1) | 21 | 5.1 (3.9, 7.2) | 0.559 | 0.550 |

| Child Characteristics | | | | | | | | | | |
|---------------------------------------|----|----------------------|----|----------------------|----|----------------------|--------|--------|--|--|
| Child age at assessment (months) | 27 | 27 (26, 34) | 26 | 29 (27, 36.2) | 21 | 29 (26, 32) | 0.623 | 0.901 | | |
| Gender | 27 | Boys=18 (66.7%) | 26 | Boys=13 (50%) | 21 | Boys=11 (52.3%) | | | | |
| Birth Anthropometry | | | | | | | | | | |
| Gestation age (weeks) | 27 | 39.0 (38.0, 40.2) | 26 | 39.0 (38.0, 40.2) | 21 | 39.4 (38.8, 40.2) | 0.920 | 0.936 | | |
| Birth weight (gm) | 27 | 2908.6 (412.5) | 26 | 2809.2 (458.6) | 21 | 2788.9 (315.9) | 0.411 | 0.277 | | |
| Birth length (cm) | 27 | 49.1 (46.8, 49.8) | 26 | 48.2 (47.4, 49.8) | 20 | 48.5 (47.2, 49.3) | 0.990 | 0.328 | | |
| Head circumference (cm) | 27 | 33.4 (1.0) | 26 | 33.1 (1.0) | 20 | 33.0 (0.9) | 0.237 | 0.142 | | |
| Cord Micronutrients | | | | | | | | | | |
| Vitamin B12 (pM) | 27 | 226.0 (138.0, 289.0) | 26 | 275.5 (181.7, 313.7) | 21 | 289.0 (167.0, 446.0) | 0.240 | 0.200 | | |
| Holo-TC (pM) | 27 | 40.7 (23.3, 81.9) | 26 | 79.4 (39.2, 125.0) | 21 | 96.1 (39.4, 125.0) | 0.021* | 0.048* | | |
| Folate (nM) | 27 | 55.9 (37.9, 70.8) | 26 | 52.0 (36.8, 68.1) | 21 | 42.7 (31.3, 80.0) | 0.473 | 0.278 | | |
| Vitamin B2 (pM) | 26 | 357 (73.7) | 25 | 316 (73.5) | 20 | 314 (67.3) | 0.053 | 0.924 | | |
| Vitamin B6-pyridoxal-5-phosphate (pM) | 12 | 29.3 (18.6, 42.7) | 13 | 25.0 (19.1, 39.5) | 13 | 17.5 (11.6, 43.9) | 0.494 | 0.298 | | |
| Vitamin B6-pyridoxal (pM) | 26 | 4.80 (3.6, 7.9) | 25 | 5.70 (4.6, 8.3) | 21 | 4.80 (3.2, 6.9) | 0.187 | 0.806 | | |
| Homocysteine (μmol/L) | 27 | 8.30 (6.8, 11.6) | 26 | 6.30 (4.8, 9.8) | 21 | 6.60 (4.6, 11.9) | 0.134 | 0.342 | | |
| BDNF (pg/ml) | 27 | 70.0 (31.0, 299.0) | 26 | 106.0 (31.0, 412.2) | 21 | 195.0 (31.0, 512.0) | 0.620 | 0.364 | | |

592 Values represented as Mean (SD), Median (25th, 75th) or n (%)

593 *p<0.05, **p<0.01 ***p<0.001 p-values calculated by t-test

594 Holo-TC, holotranscobalamin; BDNF, Brain Derived Neurotrophic Factor

595

596

597

598

599

600

601

602

603

604

605

606 **Table 2.** Comparison between placebo and supplemented groups on BSID-III domains

| BSID-III domains | Placebo Group | B12+MMN Group | B12 Group | #p value | | \$p value | |
|------------------|-----------------------|-----------------------|-----------------------|----------------------------|------------------------|----------------------------|------------------------|
| | | | | Group (B12+MMN vs Placebo) | Group (B12 vs Placebo) | Group (B12+MMN vs Placebo) | Group (B12 vs Placebo) |
| Cognitive | 90.0 (85.0, 95.0) | 90.0 (85.0, 96.2) | 95.0 (90.0, 100) | 0.969 | 0.034* | 0.781 | 0.044* |
| Motor | 94.0 (91.0, 100.0) | 95.5 (90.2, 100.0) | 97.0 (91.0, 107.0) | 0.687 | 0.818 | 0.522 | 0.384 |
| Language | 92.2 (7.8) | 93.7 (9.87) | 98.6 (10.1) | 0.556 | 0.020* | 0.633 | 0.020* |

607 Values represented as Mean (SD) or Median (25th, 75th)

608 *p<0.05

609 #P value calculated by t test

610 \$P value calculated by ANCOVA; value adjusted for maternal baseline B12 levels

611 Language performance was normally distributed, and Mean (SD) are reported





Figure 1 Study timeline and consort